ArticleGlycoconjugate journal2026
Evaluation of acylated/deacylated ghrelin, CCL20/CCR6 concentration, and IgG N-Glycan alterations in different dysplasia grades of colon adenoma.
Article in Glycoconjugate journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal adenomas represent precursor lesions in the adenoma-carcinoma sequence and are characterized by chronic low-grade inflammation. Chemokine CCL20/CCR6 signaling and metabolic hormone ghrelin have been implicated in colorectal tumorigenesis, while IgG glycosylation reflects systemic immune status. However, their interrelationship across different stages of adenoma dysplasia remains unclear. A total of 70 patients with histologically confirmed colorectal adenomas were stratified into low-grade (n = 36) and high-grade dysplasia (n = 34). Serum CCL20, CCR6, acylated and deacylated ghrelin concentrations were measured using enzyme immunoassay (ELISA), while IgG N-glycans were analyzed by hydrophilic interaction liquid chromatography-ultra performance liquid chromatography (HILIC-UPLC). Correlation analyses were performed to assess associations between inflammatory, metabolic, and glycomic parameters. No significant differences were observed between low- and high-grade dysplasia in circulating CCL20, CCR6, acylated or deacylated ghrelin, or IgG N-glycosylation profiles. A significant positive correlation between acylated and deacylated ghrelin was detected only in high-grade dysplasia. In low-grade dysplasia, CCL20 correlated significantly with deacylated ghrelin. Additional nominal associations between ghrelin, CCL20, and selected IgG glycan traits were identified but lost significance after Benjamini-Hochberg false discovery rate correction. These exploratory associations included bisecting glycans with deacylated ghrelin and CCL20 with GP20, GP21, GP1, and GP10. Although systemic inflammatory biomarkers, ghrelin isoforms, and IgG N-glycosylation did not differ between dysplasia grades, distinct correlation patterns suggest stage-specific relationships. The association between CCL20 and deacylated ghrelin in low-grade dysplasia and the strong correlation between ghrelin isoforms in high-grade dysplasia warrant further investigation.
Indexed as
Identifiers
42776302What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.